[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370474-105":59,"doc-detail-370474-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","optimal-dose-volume-histogram-thresholds-for-radiation-pneumonitis-prevention-in-lung-cancer-patients-receiving-immunotherapy","Optimal dose-volume histogram thresholds for radiation pneumonitis prevention in lung cancer patients receiving immunotherapy","","Evaluate symptomatic radiation pneumonitis incidence in lung cancer patients receiving immunotherapy combined with thoracic radiotherapy. A retrospective analysis of 389 patients (January 2015–September 2024) used propensity score matching to compare RP rates and regression modeling to determine predictors of grade ≥2 RP. Symptomatic RP occurred in 30.33% (grade ≥2) and 7.46% (grade ≥3). Immunotherapy did not increase RP risk, while lung V20 was critical, supporting V20 ≤20% as an optimal dosimetric threshold for prevention during combined-modality therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/optimal-dose-volume-histogram-thresholds-for-radiation-pneumonitis-prevention-in-lung-cancer-patients-receiving-immunotherapy/370474/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/optimal-dose-volume-histogram-thresholds-for-radiation-pneumonitis-prevention-in-lung-cancer-patients-receiving-immunotherapy/370474.png","ImageObject",300,407,{"name":92,"@type":93},"Jake","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study objective regarding radiation pneumonitis?","Question",{"text":112,"@type":113},"To evaluate the incidence of symptomatic radiation pneumonitis in lung cancer patients receiving immunotherapy and radiotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the patient data analyzed?",{"text":117,"@type":113},"A retrospective cohort of 389 patients receiving thoracic radiotherapy with or without immunotherapy was analyzed using propensity score matching, followed by univariate and multivariable regression to identify predictors of grade ≥2 RP.",{"name":119,"@type":110,"acceptedAnswer":120},"Did immunotherapy increase the risk of grade ≥2 radiation pneumonitis?",{"text":121,"@type":113},"No. Multivariable analysis found no significant association between immunotherapy administration and RP risk, and immunotherapy did not raise the risk of grade ≥2 RP.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370474,1790216942,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962084928904,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Ma etal. Radiation Oncology (2025) 20:60 [https://doi.org/10.1186/s13014-025-02639-2](https://doi.org/10.1186/s13014-025-02639-2)  \nRadiation Oncology  \nRESEARCH Open Access  \nOptimal dose-volume histogram thresholds  for radiation pneumonitis prevention in lung cancer patients receiving immunotherapy  \nYechen Ma 1†, Ziyang Feng 1†, Hao Zhou2, Xuewen Liu 1* and Zewen Song 1,2*  \nAbstract  \nObjectives To evaluate the incidence of symptomatic radiation pneumonitis (RP) in lung cancer patients receiving immunotherapy and radiotherapy.  \nMaterials and methods We retrospectively analyzed 389 lung cancer patients who underwent thoracic radiotherapy with/without immunotherapy at the Third Xiangya Hospital (January 2015-September 2024) . Propensity score matching (PSM) was employed to compare RP incidence. Univariate, multivariate, and stepwise regression analyses were conducted to identify predictors of grade ≥ 2 RP.  \nResults Symptomatic RP occurred in 30 . 33%(118/389) and 7 .46%(29/389) of patients for grades ≥ 2 and ≥ 3, respectively. Patients receiving concurrent immunotherapy-radiotherapy demonstrated a significantly lower incidence of grade ≥ 2 RP compared to other treatment groups (p \u003C 0. 05) . Multivariable analysis revealed no significant association between immunotherapy administration and RP risk. Lung V20 (≤ 20% vs. > 20%) emerged as a critical predictor: grade ≥ 2 RP incidence was 4 .05–8. 73% with V20 ≤20%, versus 53.8–65. 5% when V20 exceeded 20% . Conclusions Immunotherapy did not raise the risk of grade ≥ 2 RP. Maintaining lung V20 ≤20% may serve as an optimal dosimetric threshold for RP prevention in patients undergoing combined-modality therapy.  \nClinical trial number Not applicable.  \nKeywords Radiation pneumonitis, Lung cancer, Immunotherapy, Radiotherapy  \n†Yechen Ma and Ziyang Feng contributed equally to this work.  \n*Correspondence: Xuewen Liu [aveinliu@csu.edu.cn](aveinliu@csu.edu.cn)[ ](aveinliu@csu.edu.cn)Zewen Song [xy3songzw@csu.edu.cn](xy3songzw@csu.edu.cn)  \n1Department of Oncology, The Third Xiangya Hospital of Central South University, Changsha, China  \n2Department of Oncology, Xiangxi Autonomous Prefecture People’s Hospital, Jishou, China  \nIntroduction  \nAs the leading cause of cancer-related mortality globally, lung cancer’s aggressive nature necessitates innovative therapeutic approaches. Traditionally dominated by surgery, chemotherapy, and radiotherapy, the treatment landscape has evolved with the advent of immune checkpoint inhibitors [1–5], which have demonstrated remarkable efficacy in enhancing the body’s immune response against cancer cells. For instance, the phase III PACIFIC and GEMSTONE-301 trials established durvalumab or sugemalimab as a standard consolidation therapy for stage III NSCLC patients received definitive chemoradiotherapy (CRT) [6, 7]. Additionally, patients with  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nMa et al. Radiation Oncology (2025) 20:60  \no","cbCaiuvNePNTA0XV","https://ap.wps.com/l/cbCaiuvNePNTA0XV","pdf",2873815,"English","# Abstract\n## Objectives\n## Materials and methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the study objective regarding radiation pneumonitis?\",\"answer\":\"To evaluate the incidence of symptomatic radiation pneumonitis in lung cancer patients receiving immunotherapy and radiotherapy.\"},{\"question\":\"How was the patient data analyzed?\",\"answer\":\"A retrospective cohort of 389 patients receiving thoracic radiotherapy with or without immunotherapy was analyzed using propensity score matching, followed by univariate and multivariable regression to identify predictors of grade ≥2 RP.\"},{\"question\":\"Did immunotherapy increase the risk of grade ≥2 radiation pneumonitis?\",\"answer\":\"No. Multivariable analysis found no significant association between immunotherapy administration and RP risk, and immunotherapy did not raise the risk of grade ≥2 RP.\"}]","Optimal dose-volume histogram thresholds for radiation pneumonitis prevention in lung cancer patients receiving immunotherapy | PDF",1790188713,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c72df793f1de47e62cfc2e43f20d657.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70ba24bcb65a0047fef5b74823cf2373.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5f0dbdebf84e36cb8374400a7e222a7.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2faadc768517d711d16981125caeaa18.webp",980,1306]